GlassScriptPhysician profile
Mary Ellen Moore
NPI 1730434879
$5,724.06
in general payments reported to CMS, 2019-2025
31 companies · $754 in 2025
The $754 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $634 · 2021: $1,007 · 2022: $1,000 · 2023: $818 · 2024: $1,023 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,594.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $950.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $730.29 | 2019-2025 | Jardiance |
| Abbvie INC. | $690.42 | 2021-2025 | |
| Glaxosmithkline, LLC. | $478.88 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $447.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $346.53 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $290.43 | 2020-2025 | Farxiga, Airsupra, Fasenra |
| Otsuka America Pharmaceutical, INC. | $268.64 | 2023-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $247.97 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $186.40 | 2021-2024 | Xarelto |
| Allergan, INC. | $157.85 | 2019-2020 | |
| Astellas Pharma US INC | $154.07 | 2023-2025 | Veozah |
| Ultragenyx Pharmaceutical INC. | $125.00 | 2022 | |
| Madrigal Pharmaceuticals | $74.98 | 2025 | Rezdiffra |
| Pfizer INC. | $67.53 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $65.92 | 2022-2023 | |
| Exact Sciences Corporation | $63.29 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $50.53 | 2024-2025 | Proclaim |
| E.R. Squibb & Sons, L.L.C. | $42.97 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.96 | 2022 | |
| Ibsa Pharma INC. | $33.14 | 2022-2023 | Tirosint, Licart |
| Sunovion Pharmaceuticals INC. | $32.67 | 2020 | |
| Organon LLC | $27.42 | 2025 | Nexplanon |
| Ironwood Pharmaceuticals, INC | $25.42 | 2019 | |
| Daiichi Sankyo INC. | $21.12 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.41 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.85 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $18.38 | 2022 | |
| Sanofi Pasteur INC. | $17.83 | 2020 | |
| Amarin Pharma, INC. | $15.92 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ellen Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.